By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Therapeutics are discussed in a new report. According to news reporting originating in Berlin, Germany, by NewsRx journalists, research stated, "Understanding of the roles of noncoding RNAs (ncRNAs) within complex organisms has fundamentally changed. It is increasingly possible to use ncRNAs as diagnostic and therapeutic tools in medicine."
The news reporters obtained a quote from the research from the Charite University Hospital and School of Medicine, "Regarding disease pathogenesis, it has become evident that confinement to the analysis of protein-coding regions of the human genome is insufficient because ncRNA variants have been associated with important human diseases. Thus, inclusion of noncoding genomic elements in pathogenetic studies and their consideration as therapeutic targets is warranted. We consider aspects of the evolutionary and discovery history of ncRNAs, as far as they are relevant for the identification and selection of ncRNAs with likely therapeutic potential. Novel therapeutic strategies are based on ncRNAs, and we discuss here RNA interference as a highly versatile tool for gene silencing. RNA interference-mediating RNAs are small, but only parts of a far larger spectrum encompassing ncRNAs up to many kilobasepairs in size. We discuss therapeutic options in cardiovascular medicine offered by ncRNAs and key issues to be solved before clinical translation. Convergence of multiple technical advances is highlighted as a prerequisite for the translational progress achieved in recent years. Regarding safety, we review properties of RNA therapeutics, which may immunologically distinguish them from their endogenous counterparts, all of which underwent sophisticated evolutionary adaptation to specific biological contexts."
According to the news reporters, the research concluded: "Although our understanding of the noncoding human genome is only fragmentary to date, it is already feasible to develop RNA interference against a rapidly broadening spectrum of therapeutic targets and to translate this to the clinical setting under certain restrictions."
For more information on this research see: Cardiovascular RNA Interference Therapy: The Broadening Tool and Target Spectrum. Circulation Research, 2013;113(5):588-602. Circulation Research can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA (see also Therapeutics).
Our news correspondents report that additional information may be obtained by contacting W. Poller, Charite, Dept. of Cardiol & Pneumol, D-12200 Berlin, Germany. Additional authors for this research include J. Tank, C. Skurk and M. Gast.
Keywords for this news article include: Berlin, Europe, Germany, Cardiology, Therapeutics, Cardiovascular
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC